Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06505239 · ClinicalTrials.gov registry record · NA
Assessing the Safety and Efficacy of FSD-F2R6-A-CP in Volunteers in an Induced State of Alcohol Intoxication
A NA study of Acute Alcohol Intoxication, sponsored by Quantum Biopharma.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT06505239 is a NA study of Acute Alcohol Intoxication that has completed, run by Quantum Biopharma. The registered enrollment target is 26 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06505239, a NA study of Acute Alcohol Intoxication, has completed, sponsored by Quantum Biopharma.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
This will be a (2 visit) double-blind, randomized, placebo crossover design clinical study to assess the potential benefits of FSD-F2R6-A-CP versus a placebo by assessing its impact on side effect profiles as well as cognitive abilities, motor abilities, and breath alcohol concentration following ingestion of alcohol followed by the dietary supplement or placebo. This study will enroll healthy men and women.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT FSD-F2R6-A-CP
Study Locations (1)
Florida
- Applied Science and Performance Institute - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-07-12 |
| Est. Completion | 2024-11-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06505239
The ClinicalTrials.gov registry entry for NCT06505239 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Quantum Biopharma, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Alcohol Intoxication appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06505239 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06505239 about?
NCT06505239 is a clinical study titled "Assessing the Safety and Efficacy of FSD-F2R6-A-CP in Volunteers in an Induced State of Alcohol Intoxication". This will be a (2 visit) double-blind, randomized, placebo crossover design clinical study to assess the potential benefits of FSD-F2R6-A-CP versus a placebo by assessing its impact on side effect profiles as well as cognitive abilities, motor abilities, and breath alcohol concentration following in...
What is the current status of trial NCT06505239?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2024-07-12. Estimated completion is 2024-11-07.
What conditions does trial NCT06505239 study?
This clinical trial studies the following conditions: Acute Alcohol Intoxication.
What interventions are being tested in trial NCT06505239?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), FSD-F2R6-A-CP (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06505239?
This trial is sponsored by Quantum Biopharma, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06505239 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.